CORPORATE PARTNERS

Gene therapy is an area where cooperation between academia, the National Health Service and industry are vital for optimal development of the field. The British Society for Gene Therapy One of the ways to achieve this is to invite companies with an interest in basic or clinical aspects of gene therapy to join BSGT as Corporate Partners.

We aim to develop a close relationship with our Corporate Partners. A member of the BSGT executive (Professor John Fabre) acts as the contact point with Corporate Partners, in order to facilitate communication, discuss new ideas, address any problems as they arise, and generally to ensure that the relationship is of benefit to our Partner companies. Our objective is to work with a maximum of around 5 Corporate Partners.

Our Corporate Partners are given, at no charge, the following privileges:

• Company logos (with links to company websites) are prominently displayed on the home page at the BSGT website. This provides highly focused advertising of company profile, products, services and objectives to those interested in gene therapy, and establishes a strong presence in the gene therapy community.

• Corporate partners are allocated 10 minutes for a presentation to delegates at the annual scientific meetings, to use at their discretion for communicating company matters to the meeting.

• Corporate Partners are given a full page in the programme booklet of the annual scientific meeting, to use at their discretion for promoting company profiles, products etc to delegates.

• Corporate Partners are given a commercial stand at the annual scientific meetings. The stands of Corporate Partners are (if possible) grouped together and more prominent than normal stands.

• Corporate Partners may nominate two members of their company to become members of the Society.

• Corporate Partners are given two guaranteed places to the social functions at the annual scientific meeting.

• Corporate Partners are given one guaranteed place at a Speakers/Council dinner the evening before the annual scientific meeting. We hope that this will provide an informal venue for exchanging ideas.

• The British Society for Gene Therapy will also provide advice to our partners regarding gene therapy if requested.

• A stable and secure British Society for Gene Therapy will play a pivotal role in the development of gene therapy in the UK, for example by organising exciting annual scientific congresses, by acting as a repository of readily available expertise for the NHS, industry and the media, and by exploring and pursuing agreed objectives for the advancement of the field. We believe that a strong BSG is best achieved by requesting that our Corporate Partners provide financial support of £10,000pa, guaranteed for 3 years.

If you would like to discuss the possibility of joining BSGT as a Corporate Partner, please contact Professor John Fabre on 020 7848 5142 or email: john.fabre@kcl.ac.uk.